Japanese Pharmaceutical Industry: Recent Perspectives and Areas for Further Research
DOI:
https://doi.org/10.21423/JRS-V08SHOYOKeywords:
Japan, pharmaceutical industry, drug pricing, regulatory science, clinical development, marketing strategyAbstract
The Japanese pharmaceutical market is one of the largest in the world. The Japanese government has increasingly been trying to control rising health care costs, and as a result, pharmaceutical companies are expecting that fewer opportunities will be available to command a higher price based on higher levels of innovation; this will likely lead to decreased interest in research and development (R&D) activities. With this background, the purpose of this article is to review current perspectives for R&D by the Japanese pharmaceutical industry, and to discuss the limitations and challenges for further research from the regulatory science and management perspectives. Given the substantial amount of evidence of regulatory science and management perspectives from the pharmaceutical industry outside of Japan and the limited amount of evidence from inside of Japan, it is important to review perspectives focusing on the Japanese pharmaceutical industry in comparison with those from other countries to understand the complexities of the Japanese pharmaceutical market, as well as the limitations and challenges associated with increasing productivity.
https://doi.org/10.21423/jrs-v08shoyo
References
Afuah, A. (2002). Mapping technological capabilities into product markets and competitive advantage: the case of cholesterol drugs. Strategic Management Journal, 23(2), 171-179. https://www.doi.org/10.1002/smj.221
Aggarwal, V. A. (2019). Resource congestion in alliance networks: How a firm's partners' partners influence the benefits of collaboration. Strategic Management Journal, 41(4), 627-655. https://www.doi.org/10.1002/smj.3109
Aitken, M., Kleinrock, M., Simorellis, A., & Nass, D. (2019). The Global Use of Medicine in 2019 and Outlook to 2023: Forecasts and Areas to Watch. IQVIA Institute.
Alt, S., & Helmstadter, A. (2018). Market entry, power, pharmacokinetics: what makes a successful drug innovation? Drug Discovery Today, 23(2), 208-212. https://www.doi.org/10.1016/j.drudis.2017.09.009
Aoi, M., & Nakamura, H. (2003). Changes in external environments in the U.S. drug market and the impacts on R&D oriented pharmaceutical companies: implications for the Japanese system and R&D oriented pharmaceutical companies (in Japanese). Iryo To Shakai, 13(2), 85-111.
Asakawa, K., & Nakamura, H. (2005). Co-evolution of innovation systems in Japan's pharmaceutical and biotechnology industries (in Japanese). Iryo To Shakai, 15(1), 1-15.
Asano, K., Uyama, Y., & Tohkin, M. (2018). Factors Affecting Drug-Development Strategies in Asian Global Clinical Trials for Drug Approval in Japan. Clinical and Translational Science, 11(2), 182-188. https://www.doi.org/10.1111/cts.12520
Barber, B., IV., & Diestre, L. (2019). Pushing for speed or scope? Pharmaceutical lobbying and Food and Drug Administration drug review. Strategic Management Journal, 40(8), 1194-1218. https://www.doi.org/10.1002/smj.3021
Bardey, D., Bommier, A., & Jullien, B. (2010). Retail price regulation and innovation: Reference pricing in the pharmaceutical industry. Journal of Health Economics, 29(2), 303-316. https://www.doi.org/10.1016/j.jhealeco.2009.11.015
Berndt, E. R. (2000). International comparisons of pharmaceutical prices: what do we know, and what does it mean? Journal of Health Economics, 19(2), 283-287. https://www.doi.org/10.1016/s0167-6296(99)00043-0
Bierly, P., & Chakrabarti, A. (1996). Generic knowledge strategies in the U.S. pharmaceutical industry. Strategic Management Journal, 17(S2), 123-135. https://www.doi.org/10.1002/smj.4250171111
Brekke, K. R., Konigbauer, I., & Straume, O. R. (2007). Reference pricing of pharmaceuticals. Journal of Health Economics, 26(3), 613-642. https://www.doi.org/10.1016/j.jhealeco.2006.11.003
Chen, Y., & Schweitzer, S. O. (2008). Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region. Value in Health, 11(Suppl 1), S124-S129. https://www.doi.org/0.1111/j.1524-4733.2008.00376.x
Costa-Font, J., McGuire, A., & Varol, N. (2014). Price regulation and relative delays in generic drug adoption. Journal of Health Economics, 38, 1-9. https://www.doi.org/10.1016/j.jhealeco.2014.04.004
Danzon, P. M., & Chao, L. W. (2000). Cross-national price differences for pharmaceuticals: how large, and why? Journal of Health Economics, 19(2), 159-195. https://www.doi.org/10.1016/s0167-6296(99)00039-9
Danzon, P. M., Wang, Y. R., & Wang, L. (2005). The impact of price regulation on the launch delay of new drugs -- evidence from twenty-five major markets in the 1990s. Health Economics, 14(3), 269-292. https://www.doi.org/10.1002/hec.931
DiMasi, J. A., Reichert, J. M., Feldman, L., & Malins, A. (2013). Clinical approval success rates for investigational cancer drugs. Clinical Pharmacology & Therapeutics, 94(3), 329-335. https://www.doi.org/10.1038/clpt.2013.117
Eger, S., & Mahlich, J. C. (2014). Pharmaceutical regulation in Europe and its impact on corporate R&D. Health Economics Review, 4(1), 23. https://www.doi.org/10.1186/s13561-014-0023-5
Fukuda, T., & Shiroiwa, T. (2019). Application of economic evaluation of pharmaceuticals and medical devices in Japan. Journal of the National Institute of Public Health, 68(1), 27-33.
Ghislandi, S. (2011). Competition and the reference pricing scheme for pharmaceuticals. Journal of Health Economics, 30(6), 1137-1149. https://www.doi.org/10.1016/j.jhealeco.2011.08.010
Goldsmith, A. D., & Varela, F. E. (2017). Fragmentation in the biopharmaceutical industry. Drug Discovery Today, 22(2), 433-439. https://www.doi.org/10.1016/j.drudis.2016.10.013
Golec, J., & Vernon, J. A. (2010). Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms. Pharmacoeconomics, 28(8), 615-628. https://www.doi.org/10.2165/11535580-000000000-00000
Golec, J., Hegde, S., & Vernon, J. A. (2010). Pharmaceutical R&D Spending and Threats of Price Regulation. Journal of Financial and Quantitative Analysis, 45(1), 239-264. https://www.doi.org/10.1017/S0022109009990512
Grabowski, H., & Vernon, J. (2000). The determinants of pharmaceutical research and development expenditures. Journal of Evolutionary Economics, 10(1), 201-215.
Gregson, N., Sparrowhawk, K., Mauskopf, J., & Paul, J. (2005). Pricing medicines: theory and practice, challenges and opportunities. Nature Reviews Drug Discovery, 4(2), 121-130. https://www.doi.org/10.1038/nrd1633
Guan, X., Wushouer, H., Yang, M., Han, S., Shi, L., Ross-Degnan, D., & Wagner, A. K. (2019). Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study. BMJ Open, 9(11), e031658. https://www.doi.org/10.1136/bmjopen-2019-031658
Guler, I., & Nerkar, A. (2012). The impact of global and local cohesion on innovation in the pharmaceutical industry. Strategic Management Journal, 33(5), 535-549. https://www.doi.org/10.1002/smj.957
Harrison, R. K. (2016). Phase II and phase III failures: 2013-2015. Nature Reviews Drug Discovery, 15, 817-818. https://www.doi.org/10.1038/nrd.2016.184
Hasegawa, M. (2020). HTA system implemented in Japan. PharmacoEconomics & Outcomes News, 846, 15. https://www.doi.org/10.1007/s40274-020-6554-6
Hasegawa, M., Komoto, S., Shiroiwa, T., & Fukuda, T. (2020). Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System. Value in Health, 23(1), 43-51. https://www.doi.org/10.1016/j.jval.2019.10.005
Hashimoto, A., & Haneda, S. (2008). Measuring the change in R&D efficiency of the Japanese pharmaceutical industry. Research Policy, 37(10), 1829-1836. https://www.doi.org/10.1016/j.respol.2008.08.004
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014). Clinical development success rates for investigational drugs. Nature Biotechnology, 32(1), 40-51. https://www.doi.org/10.1038/nbt.2786
Hirai, Y., Kinoshita, H., Kusama, M., Yasuda, K., Sugiyama, Y., & Ono, S. (2010). Delays in New Drug Applications in Japan and Industrial R&D Strategies. Clinical Pharmacology & Therapeutics, 87(2), 212-218. https://www.doi.org/10.1038/clpt.2009.215
Hirai, Y., Yamanaka, Y., Kusama, M., Ishibashi, T., Sugiyama, Y., & Ono, S. (2012). Analysis of the success rates of new drug development in Japan and the lag behind the U.S. Health Policy, 104(3), 241-246. https://www.doi.org/10.1016/j.healthpol.2011.11.008
Honig, P. K. (2014). Recent trends and success factors in reducing the lag time to approval of new drugs in Japan. Clinical Pharmacology & Therapeutics, 95(5), 467-469. https://www.doi.org/10.1038/clpt.2013.256
Ichimaru, K., Toyoshima, S., & Uyama, Y. (2010). PMDA's Challenge to Accelerate Clinical Development and Review of New Drugs in Japan. Clinical Pharmacology & Therapeutics, 88(4), 454-457. https://www.doi.org/10.1038/clpt.2010.190
Ide, H., Yasunaga, H., Imamura, T., & Ohe, K. (2007). Price differences between Japan and the U.S. for medical materials and how to reduce them. Health Policy, 82(1), 71-77. https://www.doi.org/10.1016/j.healthpol.2006.08.003
Ikegami, N., Ikeda, S., & Kawai, H. (1998). Why Medical Care Costs in Japan Have Increased Despite Declining Prices for Pharmaceuticals. PharmacoEconomics, 14(Suppl 1), 97-105. https://www.doi.org/10.2165/00019053-199814001-00012
Ito, K., & Lechevalier, S. (2010). Why some firms persistently out-perform others: investigating the interactions between innovation and exporting strategies. Industrial and Corporate Change, 19(6), 1997-2039. https://www.doi.org/10.1093/icc/dtq056
Kato, Y., Matsui, T., Hane, Y., Abe, J., Ueda, N., Sasaoka, S., Motooka, Y., Hatahira, H., Umetsu, R., & Nakamura, M. (2016). Analysis of new drug price calculation according to National Health Insurance (NHI) drug price list in Japan (in Japanese). Regulatory Science of Medical Products, 6(2), 171-183.
Kavusan, K., & Frankort, H. T. W. (2019). A behavioral theory of alliance portfolio reconfiguration: Evidence from pharmaceutical biotechnology. Strategic Management Journal, 40(10), 1668-1702. https://www.doi.org/10.1002/smj.3041
Kesselheim, A. S., & Avorn, J. (2013). The most transformative drugs of the past 25 years: a survey of physicians. Nature Reviews Drug Discovery, 12(6), 425-431. https://www.doi.org/10.1038/nrd3977
Kesselheim, A. S., Wang, B., & Avorn, J. (2013). Defining "Innovativeness" in Drug Development: A Systematic Review. Clinical Pharmacology & Therapeutics, 94(3), 336-348. https://www.doi.org/10.1038/clpt.2013.115
Kido, K., Matsumaru, N., & Tsukamoto, K. (2019). Health Technology Assessment in Japan: A Pharmaceutical Industry Perspective. Therapeutic Innovation & Regulatory Science, 53(4), 472-480. https://www.doi.org/10.1177/2168479018791136
Kneller, R. (2010). The importance of new companies for drug discovery: origins of a decade of new drugs. Nature Reviews Drug Discovery, 9(11), 867-882. https://www.doi.org/10.1038/nrd3251
Koenig, P., & MacGarvie, M. (2011). Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe. Journal of Health Economics, 30(5), 950-965. https://www.doi.org/10.1016/j.jhealeco.2011.07.005
Kogure, S., Koyama, N., & Hidaka, S. (2017). Utilization of the Bridging Strategy for the Development of New Drugs in Oncology to Avoid Drug Lag. Journal of Clinical Pharmacology, 57(11), 1479-1490. https://www.doi.org/10.1002/jcph.951
Kogushi, K., Ogawa, T., & Ikeda, S. (2019). An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan. Expert Review of Pharmacoeconomics & Outcomes Research. https://www.doi.org/10.1080/14737167.2019.1665513
Kondo, H., Shimada, Y., & Ozawa, T. (2019). Promotion of Japan's participation in global clinical trials. Drug Discovery Today, 24(4), 939-942. https://www.doi.org/10.1016/j.drudis.2019.01.016
Kyle, M. K. (2007). Pharmaceutical Price Controls and Entry Strategies. The Review of Economics and Statistics, 89(1), 88-99.
Liu, Y-M., Yang, Y-H. K., & Hsieh, C-R. (2012). Regulation and competition in the Taiwanese pharmaceutical market under national health insurance. Journal of Health Economics, 31(3), 471-483. https://www.doi.org/10.1016/j.jhealeco.2012.03.003
Liu, G., Wu, E. Q., Ahn, J., Kamae, I., Xie, J., & Yang, H. (2020). The Development of Health Technology Assessment in Asia: Current Status and Future Trends. Value in Health Regional Issues, 21, 39-44. https://www.doi.org/10.1016/j.vhri.2019.08.472
Lu, J. W., & Beamish, P. W. (2004). International Diversification and Firm Performance: The S-curve Hypothesis. Academy of Management Journal, 47(4), 598-609. https://www.doi.org/10.5465/20159604
Macher, J. T., & Boerner, C. (2012). Technological development at the boundaries of the firm: a knowledge-based examination in drug development. Strategic Management Journal, 33(9), 1016-1036. https://www.doi.org/10.1002/smj.1956
Maeda, H., & Kurokawa, T. (2015a). Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan? International Journal of Clinical Oncology, 20(6), 1072-1080. https://www.doi.org/10.1007/s10147-015-0825-4
Maeda, H., & Kurokawa, T. (2015b). Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States. The Journal of Clinical Pharmacology, 55(5), 481-489. https://www.doi.org/10.1002/jcph.458
Mahlich, J. C., & Roediger-Schluga, T. (2006). The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan. Review of Industrial Organization, 28(2), 145-164. https://www.doi.org/10.1007/s11151-006-0010-z
Matsushita, S., Tachibana, K., & Kondoh, M. (2019). The Clinical Innovation Network: a policy for promoting development of drugs and medical devices in Japan. Drug Discovery Today, 24(1), 4-8. https://www.doi.org/10.1016/j.drudis.2018.05.026
Miller, K., L., & Lanthier, M. (2015). Regulatory watch: Innovation in biologic new molecular entities: 1986–2014. Nature Reviews Drug Discovery, 14(2), 83. https://www.doi.org/10.1038/nrd4535
Ministry of Health, Labour and Welfare. (2002). Pharmaceutical Industry Vision (in Japanese). Retrieved from https://www.mhlw.go.jp/shingi/2002/08/dl/s0830-1c.pdf
Ministry of Health, Labour and Welfare. (2007a). Action Program for Promotion of the Safe Use of Generic Drugs (in Japanese). Retrieved from https://www.mhlw.go.jp/houdou/2007/10/dl/h1015-1a.pdf
Ministry of Health, Labour and Welfare. (2007b). New Pharmaceutical Industry Vision (in Japanese). Retrieved from https://www.mhlw.go.jp/houdou/2007/08/dl/h0830-1b.pdf
Ministry of Health, Labour and Welfare. (2012). Promotion of the Use of Generic Drugs (in Japanese). Retrieved from https://www.mhlw.go.jp/english/policy_report/
Ministry of Health, Labour and Welfare. (2013). Pharmaceutical Industry Vision 2013 (in Japanese). Retrieved from https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iryou/shinkou/dl/vision_2013a.pdf
Ministry of Health, Labour and Welfare. (2016a). Basic Policy for Fundamental Reform of the Drug Pricing System (in Japanese). Retrieved from https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000146567.pdf
Ministry of Health, Labour and Welfare. (2016b). Central Social Insurance Medical Council (in Japanese). Retrieved from https://www.mhlw.go.jp/stf/shingi2/0000142573.html
Ministry of Health, Labour and Welfare. (2018). Update of Drug Pricing System in Japan [Presentation]. Retrieved from https://www.mhlw.go.jp/content/11123000/000335166.pdf
Miraldo, M. (2009). Reference pricing and firms' pricing strategies. Journal of Health Economics, 28(1), 176-197.
Morioka, K., Takayama, A., & Narukawa, M. (2017). Investigation of Characteristics of Long-Selling Drugs in Japan. Regulatory Science of Medical Products, 7(3), 151-162. https://www.doi.org/10.14982/rsmp.7.151
Nakajima, R., & Aruga, A. (2017). Analysis of New Drug Pricing and Reimbursement for Antibody Agents for Cancer Treatment in Japan. Regulatory Science of Medical Products, 7(3), 173-184. https://www.doi.org/10.14982/RSMP.7.173
Nakamura, H. (2005). Toward construction of Japan's new drug pricing system: aiming at financially improving Japan's national health insurance system and at stimulating R&D activities of innovative drugs in Japan (in Japanese). Iryo To Shakai, 15(1), 97-109.
Nakamura, H. (2007). Perspectives on structural changes in the pharmaceutical industry and new types of M&A and alliance: from the viewpoint of consistency between structural changes and the existing business model (in Japanese). Iryo To Shakai, 17(1), 39-53.
Nakamura, H., & Wakutsu N. (2019). Reducing pharmaceutical reimbursement price risk to lower national health expenditures without lowering R&D incentives. International Journal of Economic Policy Studies, 13(1), 75-88. https://www.doi.org/10.1007/s42495-018-0002-7
Nambu, T. (1997). The industrial organization of pharmaceuticals: the consequences of price regulation in Japan (in Japanese). Iryo To Shakai, 7(1), 3-15.
Patterson, J. A., & Carroll, N. V. (2020). Should the United States government regulate prescription prices? A critical review. Research in Social and Administrative Pharmacy, 16(5), 717-723. https://www.doi.org/10.1016/j.sapharm.2019.06.010
Penner-Hahn, J., & Shaver, J. M. (2005). Does international research and development increase patent output? An analysis of Japanese pharmaceutical firms. Strategic Management Journal, 26(2), 121-140. https://www.doi.org/10.1002/smj.436
Pharmaceuticals and Medical Devices Agency. (2007). Basic Principles on Global Clinical Trials. Retrieved from https://www.pmda.go.jp/files/000153265.pdf
Pharmaceuticals and Medical Devices Agency. (2014a). Basic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials. Retrieved from https://www.pmda.go.jp/files/000157777.pdf
Pharmaceuticals and Medical Devices Agency. (2014b). Guidance for Establishing Safety in First-in-Human Studies during Drug Development (in Japanese). Retrieved from https://www.pmda.go.jp/files/000208201.pdf
Pharmaceuticals and Medical Devices Agency. (2018). Drug Lag Estimation (in Japanese). Retrieved from https://www.pmda.go.jp/files/000233084.pdf
Pisani, N., Garcia-Bernardo, J., & Heemskerk, E. (2020). Does it pay to be a multinational? A large-sample, cross-national replication assessing the multinationality-performance relationship. Strategic Management Journal, 41(1), 152-172. https://www.doi.org/10.1002/smj.3087
Porter, M. E., & van der Linde, C. (1995). Toward a New Conception of the Environment-Competitiveness Relationship. Journal of Economic Perspectives, 9(4), 97-118. https://www.doi.org/10.1257/jep.9.4.97
Ridley, D. B. (2007). International Price Comparisons for Novel and Follow‐on Drugs. Value in Health, 10(6), 510-511. https://www.doi.org/10.1111/j.1524-4733.2007.00238.x
Ringel, M. S., & Choy, M. K. (2017). Do large mergers increase or decrease the productivity of pharmaceutical R&D? Drug Discovery Today, 22(12), 1749-1753. https://www.doi.org/10.1016/j.drudis.2017.06.002
Rokuda, M., Matsumaru, N., & Tsukamoto, K. (2018). Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan. Clinical Therapeutics, 40(2), 284-295. https://www.doi.org/10.1016/j.clinthera.2017.12.010
Roughead, E. E., Lopert, R., & Sansom, L. N. (2007). Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the United States. Value in Health, 10(6), 514-520. https://www.doi.org/10.1111/j.1524-4733.2007.00206.x
Ryu, W., Reuer, J. J., & Brush, T. H. (2020). The effects of multimarket contact on partner selection for technology cooperation. Strategic Management Journal, 41(2), 267-289. https://www.doi.org/10.1002/smj.3106
Sams-Dodd, F. (2007). Research & market strategy: how choice of drug discovery approach can affect market position. Drug Discovery Today, 12(7-8), 314-318. https://www.doi.org/10.1016/j.drudis.2007.02.014
Shibata, S., & Suzuki, T. (2018) The pharmaceutical market and drug development prognosis in Japan: Current and future perspectives according to pharmacological classes. Journal of Generic Medicines, 14(2), 70-80. https://www.doi.org/10.1177/1741134317737344
Shibata, S., Chiba, K., & Suzuki, T. (2017a). Downward trend in review time in Pharmaceuticals and Medical Devices Agency in Japan under the unique premium rewards system of the Japanese pharmaceutical market. American Journal of Pharmacy and Health Research, 5(7), 25-36.
Shibata, S., Chiba, K., & Suzuki, T. (2017b). Downward trend in review time in Pharmaceuticals and Medical Devices Agency in Japan under the unique premium rewards system of the Japanese pharmaceutical market: 2nd report. American Journal of Pharmacy and Health Research, 5(7), 37-52.
Shibata, S., Uemura, R., & Suzuki T. (2016a). Comparative analysis between the top-selling drugs in the Japanese pharmaceutical market and those in the United States, the United Kingdom, France, and Germany. Therapeutic Innovation & Regulatory Science, 50(2), 221-227. https://www.doi.org/10.1177/2168479015604182
Shibata, S., Uemura, R., & Suzuki, T. (2016b). Evaluating the effectiveness of repricing for market expansion in the Japanese drug pricing system. Therapeutic Innovation & Regulatory Science, 50(6), 751-758. https://www.doi.org/10.1177/2168479016652927
Shibata, S., Uemura, R., & Suzuki, T. (2016c). Factors that affect the acquisition of reward premiums for promotion of innovative drug discovery in Japan. Therapeutic Innovation & Regulatory Science, 50(1), 56-65. https://www.doi.org/10.1177/2168479015596007
Shibata, S., Uemura, R., & Suzuki, T. (2016d). Impact of premium rewards for the promotion of innovative drug discovery on the Japanese pharmaceutical market: An analysis by therapeutic area. Therapeutic Innovation & Regulatory Science, 50(1), 49-55. https://www.doi.org/10.1177/2168479015600205
Shibata, S., Uemura, R., Chiba, K., & Suzuki, T. (2016). A comprehensive analysis of factors that contribute to conditional approval and all-case surveillance designations that subsequently lead to shortening of review times in Japan. Journal of Regulatory Science, 4(1), 1-9. https://www.doi.org/10.21423/jrs-v04n01p001
Shibata, S., Fukumoto, D., Suzuki, T., & Ozaki, K. (2020a). A Comparative Study of the Market Configuration of the Japanese Pharmaceutical Market Using the Gini Coefficient and Herfindahl–Hirschman Index. Therapeutic Innovation & Regulatory Science, 54(5), 1047-1055. https://www.doi.org/10.1007/s43441-020-00122-6
Shibata, S., Fukumoto, D., Suzuki, T., & Ozaki, K. (2020b). Analyzing upward deviation of actual vs predicted drug sales in Japan for a reasonable drug-pricing policy. Therapeutic Innovation & Regulatory Science, 54(3), 544-551. https://www.doi.org/10.1177/2168479019860123
Shibata, S., Kawaguchi, H., Uemura, R., & Suzuki, T. (2016). Emerging growth of orphan drugs for neurological diseases in Japan: potential benefits for both patients and pharmaceutical companies. Journal of Regulatory Science, 4(3), 7-13. https://www.doi.org/10.21423/jrs-v04n03p007
Shibata, S., Matsushita, M., Saito, Y., & Suzuki, T. (2017). Optimal anti-cancer drug profiles for effective penetration of the anti-cancer drug market by generic drugs in Japan. Therapeutic Innovation & Regulatory Science, 52(4), 442-448. https://www.doi.org/10.1177/2168479017749513
Shibata, S., Matsushita, M., Saito, Y., & Suzuki, T. (2018). Anticancer drug prescription patterns in Japan: future directions in cancer therapy. Therapeutic Innovation & Regulatory Science, 52(6), 718-723. https://www.doi.org/10.1177/2168479017751404
Shibata, S., Wayama, Y., Tsuyuki, A., Matsushita, M., Chiba, K., Matsuki, E., Okamoto, S., & Suzuki, T. (2017). An empirical study of the prescription pattern of drugs for hematological malignancies in Japan from 2010-2014. Biological and Pharmaceutical Bulletin, 40(6), 894-901. https://www.doi.org/10.1248/bpb.b17-00111
Shirotani, M., Kurokawa, T., & Chiba, K. (2014). Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan. The Journal of Clinical Pharmacology, 54(7), 753-764. https://www.doi.org/10.1002/jcph.273
Shirotani, M., Suwa, T., Kurokawa, T., & Chiba, K. (2014). Efficient clinical trials in Japan: bridging studies versus participation in global clinical trials. The Journal of Clinical Pharmacology, 54(4), 438-445. https://www.doi.org/10.1002/jcph.216
Suzuki, M., & Nakamura, H. (1998). German reference price system and the effects on drug prices, prescription volume, and R&D incentives (in Japanese). Iryo To Shakai, 8(3), 17-38.
Takayama, A., Kobayashi, E., Nakamura, T., & Narukawa, M. (2017). Quantitative assessment of premium rates for clinical usefulness in new drug price calculation in Japan. Therapeutic Innovation & Regulatory Science, 51(5), 582-588. https://www.doi.org/10.1177/2168479017696270
Takayama, A., & Narukawa, M. (2016a). Investigation of factors affecting the degree of price gap between the national health insurance reimbursement price and the actual market price of new drugs (in Japanese). Regulatory Science of Medical Products, 6(3), 295-305. https://www.doi.org/10.14982/rsmp.6.295
Takayama, A., & Narukawa, M. (2016b). Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs. Therapeutic Innovation & Regulatory Science, 50}(3), 361-367. https://www.doi.org/10.1177/2168479015619202
Takayama, A., & Narukawa, M. (2017). Comparison of New Drug Accessibility and Price Between Japan and Major European Countries. Therapeutic Innovation & Regulatory Science, 51(5), 604-611. https://www.doi.org/10.1177/2168479017706716
Teramae, F., Makino, T., Lim, Y., Sengoku, S., & Kodama, K. (2020). International Strategy for Sustainable Growth in Multinational Pharmaceutical Companies. Sustainability, 12(3), 867. https://www.doi.org/10.3390/su12030867
Thomas, L. G., III. (2004). Are we all global now? Local vs. foreign sources of corporate competence: the case of the Japanese pharmaceutical industry. Strategic Management Journal, 25(8-9), 865-886. https://www.doi.org/10.1002/smj.420
Thomke, S., & Kuemmerle, W. (2002). Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery. Strategic Management Journal, 23(7), 619-635. https://www.doi.org/10.1002/smj.242
Thakor, R. T., Anaya, N., Zhang, Y., Vilanilam, C., Siah, K. W., Wong, C. H., & Lo, A. W. (2017). Just how good an investment is the biopharmaceutical sector? Nature Biotechnology, 35(12), 1149-1157. https://www.doi.org/10.1038/nbt.4023
Tominaga, T., Ando, Y., & Kondo, T. (2012). International Vision and Strategy for Drug Regulatory Authority: The PMDA's International Vision. Clinical Pharmacology & Therapeutics, 92(3), 349-351. https://www.doi.org/10.1038/clpt.2012.90
Ueno, T., Asahina, Y., Tanaka, A., Yamada, H., Nakamura, M., & Uyama, Y. (2014). Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in Japan. Clinical Pharmacology & Therapeutics, 95(5), 533-541. https://www.doi.org/10.1038/clpt.2013.223
Wakutsu, N., & Nakamura, H. (2015a). Analyzing the benefits from new NHI drug pricing system in Japan: factor decomposition and simulation (in Japanese). Iryo To Shakai, 25(2), 205-220. https://www.doi.org/10.4091/iken.25.205
Wakutsu, N., & Nakamura, H. (2015b). New NHI drug-pricing system in Japan: incentives for R&D and budget neutrality. International Journal of Economic Policy Studies, 10(1), 1-12. https://www.doi.org/10.1007/BF03405759
Wettstein, D. J., & Boes, S. (2019). Effectiveness of national pricing policies for patent-protected pharmaceuticals in the OECD: a systematic literature review. Applied Health Economics and Health Policy, 17(2), 143-162. https://www.doi.org/10.1007/s40258-018-0437-z
Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. Biostatistics, 20(2), 273-286. https://www.doi.org/10.1093/biostatistics/kxx069
Wright, D. J. (2004). The drug bargaining game: pharmaceutical regulation in Australia. Journal of Health Economics, 23(4), 785-813. https://www.doi.org/10.1016/j.jhealeco.2003.11.003
Xin, Y. J., Hubbard-Lucey, V. M., & Tang, J. (2019). Immuno-oncology drug development goes global. Nature Reviews Drug discovery, 18(12), 899-900. https://www.doi.org/10.1038/d41573-019-00167-9
Yamashita, K., Kaneko, M., & Narukawa, M. (2019). A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers. Clinical Pharmacology & Therapeutics, 105(1), 153-160. https://www.doi.org/10.1002/cpt.1136
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Shoyo Shibata, Koken Ozaki, Takeshi Suzuki
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
By submitting content to the Journal of Regulatory Science (JRS), authors agree to the following terms:
- Authors retain copyright and grant the JRS the right of first publication. Authors retain patent, trademark, and other intellectual property rights (including research data) and grant third parties the right to use, reproduce, and share the article according to the Creative Commons — Attribution-NonCommercial 4.0 International — CC BY-NC 4.0 license agreement. The JRS is an open access journal and, as a result, articles are free to use with proper acknowledgment of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process.
- If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article.
- The publication of the submission has been approved by all co-authors and responsible authorities at the institute or organization where the work has been carried out.
- Copyright has not been breached in seeking publication of the submission.
